CD105 (Endoglin): A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation

Donghui Liu, Shant Kumar, Jason Ashworth, Kamela Ali, Abdulmannan Fadel, Baoqiang Guo, Mark Slevin

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: CD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. Materials and Methods: In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. Results: L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. Conclusion: L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression.

Original languageEnglish
Pages (from-to)1219-1229
Number of pages11
JournalAnticancer Research
Volume41
Issue number3
DOIs
Publication statusPublished - Mar 2021
Externally publishedYes

Keywords

  • Angiogenesis
  • CD105
  • Cell signalling
  • MAPK
  • TGF-β1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'CD105 (Endoglin): A potential anticancer therapeutic inhibits mitogenesis and map kinase pathway activation'. Together they form a unique fingerprint.

Cite this